204376-48-7

Basic information

• Product Name: BOC-AMCP-OH
• Synonyms: 1-(TERT-BUTYLOXYCARBONYL-AMINOMETHYL)-CYCLOPROPYL-1-CARBOXYLIC ACID;1-(T-BUTYLOXYCARBONYL-AMINOMETHYL)-CYCLOPROPYL-1-CARBOXYLIC ACID;1-(BOC-AMINOMETHYL)CYCLOPROPYL-1-CARBOXYLIC ACID;BOC-ACPA-OH;BOC-AMCP-OH;1-{[(tert-butoxycarbonyl)amino]methyl}cyclopropanecarboxylic acid;1-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]cyclopropanecarboxylic acid;1-Bocaminomethyl-cyclopropanecarboxylic acid, 98%
• CAS NO: 204376-48-7
• Molecular Formula: C₁₀H₁₇NO₄
• Molecular Weight: 215.25
• Mol File: 204376-48-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 118-122.°C
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BOC-AMCP-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-AMCP-OH(204376-48-7)
• EPA Substance Registry System: BOC-AMCP-OH(204376-48-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 204376-48-7(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Upstream product

• 220145-17-5 methyl (<<(tert-butoxy)carbonyl>amino>methyl)cyclopropane-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 139126-45-7 1-(aminomethyl)cyclopropanecarboxylic acid 
• 6914-79-0 1-cyano-cyclopropanecarboxylic acid 
• 6914-73-4 methyl 1-cyanocyclopropanecarboxylate 
• 914226-26-9 1-aminomethyl-cyclopropanecarboxylic acid methyl ester 
• 1421601-23-1 1-(aminomethyl)cyclopropane-1-carboxylic acid hydrochloride 
• 1558-81-2 1-carbethoxy-1-cyanocyclopropane 

Downstream Products

• 204376-51-2 (S)-2-{[1-(tert-Butoxycarbonylamino-methyl)-cyclopropanecarbonyl]-amino}-4-methyl-pentanoic acid (E)-(1S,2R)-1-{(E)-3-[(R)-2-(3-chloro-4-methoxy-phenyl)-1-(2,2,2-trichloro-ethoxycarbonyl)-ethylcarbamoyl]-allyl}-2-methyl-4-phenyl-but-3-enyl ester 
• 204376-52-3 (S)-2-[(1-Aminomethyl-cyclopropanecarbonyl)-amino]-4-methyl-pentanoic acid (E)-(1S,2R)-1-{(E)-3-[(R)-1-carboxy-2-(3-chloro-4-methoxy-phenyl)-ethylcarbamoyl]-allyl}-2-methyl-4-phenyl-but-3-enyl ester 
• 1149352-56-6 methyl N-benzyl-N-[(1-{[(tert-butoxycarbonyl)amino]methyl}cyclopropyl)carbonyl]-L-alaninate 
• 153248-46-5 1-hydroxymethyl-1-(tert-butoxycarbonylaminomethyl)cyclopropane 
• 1360828-57-4 tert-butyl ((1-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)phenylsulfonylcarbamoyl)cyclopropyl)methyl)carbamate 
• 153248-47-6 tert-butyl ((1-formylcyclopropyl)methyl)carbamate 

Relevant articles and documents

TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR

Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D+ having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R1)(R2)OC(O)ANHC(═O)—.

Compound as well as preparation method and medical application thereof

The invention provides a compound as well as a preparation method and medical application thereof, the compound has a structure as shown in a general formula (I), and can also be a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer, or a mixture form thereof, or a pharmaceutically acceptable salt thereof. According to the compound with the structure as shown in the general formula (I)provided by the invention, a specific main chain structure and a corresponding substituent group are selected, so that the obtained compound can be used as an arginase inhibitor, is relatively high in activity, and has a potential treatment prospect in various diseases.

NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.